Aclarion, Inc., a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent covers the company’s use of machine learning to analyze magnetic resonance spectroscopy (MRS) data for identifying biomarkers associated with chronic low back pain. This intellectual property strengthens Aclarion’s ability to scale its cloud-based platform, Nociscan, by automating biomarker identification, accelerating report generation, and reducing manual quality reviews.
Chronic low back pain affects approximately 266 million people worldwide, and Aclarion’s technology aims to address this underserved market by providing physicians with clinically actionable insights. The Nociscan platform converts complex MRS spectral data into standardized classifications that help distinguish painful from non-painful discs in the spine. The newly issued patent specifically protects machine learning models that extract quantitative biomarkers and includes AI-based automated data quality controls that detect and exclude low-quality signals, such as excessive lipids or spectral artifacts. This capability is expected to ensure consistent, reproducible outputs across different imaging systems and clinical sites, a key step toward broader adoption.
Brent Ness, Chief Executive Officer of Aclarion, stated, “This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice.” He added that combining proprietary signal processing with machine learning builds a scalable and defensible approach to pain evaluation while enabling strong gross margin expansion. The company’s intellectual property portfolio now includes 64 issued and pending patents worldwide, reinforcing its competitive position in the chronic low back pain market.
Clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. Aclarion’s SaaS platform receives MRS data from MRI machines via a cloud connection, processes it with proprietary algorithms, and returns insights to help physicians optimize treatment strategies. The patent’s focus on AI-driven automation is particularly significant for scaling operations without proportional increases in manual oversight, potentially improving efficiency and margins.
The full patent can be read here. For more information about Aclarion and its latest news, visit the company’s newsroom or find a Nociscan center via the site map.
Aclarion is a healthcare technology company that leverages MRS, biomarkers, and augmented intelligence to optimize clinical treatments. Its Nociscan platform is the first evidence-supported SaaS tool to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The company continues to expand its intellectual property and commercial footprint in the chronic low back pain market, which remains a significant global healthcare challenge.
